Bristol Myers Lowered To Equal Weight On Valuation At Morgan Stanley - Bristol-Myers Squibb (NYSE:BMY)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a note out this morning, analyst David Risinger of Morgan Stanley lowered his rating on Bristol Myers (NYSE: BMY) from Overweight to Equal-Weight, but maintained his $60 price objective.The change is attributed to the recent rally in the shares, with BMY having rallied 17 percent since October 2. With the stock now trading just below the $60 price target (closed at $58.61), he feels an equal-weight rating is now appropriate. Morgan Stanley Investment Thesis-We expect rising pipeline enthusiasm to drive stock outperformance.-BMY should trade at a significant premium to group P/E due to strong pipeline.-BMY stock is likely to be volatile (positive/negative) on immuno-oncology (nivo, or PD-1) newsflow.Shares of BMY are trading slightly lower in pre-market trade at 58.32

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!